Search of New Opportunities of Pharmacological Protection at the Early Stages of a Non-Alcoholic Fatty Liver Disease Associated With Obesity and Metabolic Syndrome

Abstract

This article provides the rationale for the pharmacological correction of non-alcoholic fatty liver disease. This is due to the fact that non-alcoholic steatohepatosis of the liver is a slowly progressing disease. Most often, non-alcoholic steatohepatosis progresses to non-alcoholic steatohepatitis, less commonly fibrosis. It should also be noted that if you do not intervene during the disease, steatohepatitis can transform into cirrhosis, bypassing the stage of liver fibrosis. At the same time, the prevalence of non-alcoholic fatty liver dis-ease progressively increases with the age of patients. Thus, the maximum prevalence of non-alcoholic steatosis was noted in the age group of 70–80 years, non-alcoholic steatohepatitis in patients 50–59 years old. Thus, pharmacotherapy of nonalcoholic fatty liver disease should be based on the basic principle of geriatric pharmacotherapy: safety if long-term use of drugs is necessary. In this regard, it substantiates the possibility of using the essential amino acid methionine and flavolignan complex of the fruits of milk thistle for the correction of metabolic conditions associated with non-alcohol steatohepatitis. Keywords—non-alcoholic fatty liver disease, non-alcohol steatohepatitis, geriatric pharmacotherapy, methionine, flavolignan complex